Home Tags Monomethyl auristatin E

Tag: monomethyl auristatin E

Interim Results from Ongoing Studies of Brentuximab Vedotin + Nivolumab in...

Multiple presentations evaluating brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda*) across a broad range of Hodgkin lymphoma (HL) settings were presented at the 11th International Symposium...

Four Ways to Show Nonobviousness of ADC Inventions

As research continues to progress and the scientific community’s appreciation for the power of ADCs has grown, so have the numbers. FDA has now approved at least four ADCs, and hundreds more are in development. The number of patent applications has also grown, with the U.S. Patent and Trademark Office (USPTO) publishing over two hundred patent applications with claims to ADC inventions in the last two years alone.

ADCs – The Dawn of a New Era?

Two decades ago, ADCs were hailed as a major breakthrough, especially in the area of oncology therapeutics. The concept of delivering a potent drug payload directly to the site of the tumor for maximum effect with minimal damage caused to non-cancerous cells was viewed as, if not the Holy Grail of cancer treatment, at least a significant advance towards precision medicine. However, the concept has proved difficult to translate into clinical success.

New Hydrophilic Auristatin Payload Improves Antibody-Drug Conjugate Efficacy and Biocompatibility

Antibody-drug conjugates or ADCs, which link an antibody to a potent, small-molecule, cytotoxic, cell-killing, chemotherapeutic agent, use the target-specificity of monoclonal antibodies or antibody...

New Phase I Study with SGN-CD48A in Relapsed or Refractory Multiple...

Multiple myeloma is an incurable hematologic malignancy formed by malignant or transformed plasma cells in which the cancerous plasma cells can crowd out healthy...

Updated Phase I Data for Ladiratuzumab Vedotin in Patients with Triple...

Data from an ongoing phase I clinical trial evaluating ladiratuzumab vedotin, also known as SGN-LIV1A, in patients with metastatic triple negative breast cancer presented...

Polatuzumab Vedotin + Bendamustine and Rituxan Increased Complete Response Rates in...

Positive results from the randomized Phase II GO29365-study (NCT02257567) that compared polatuzumab vedotin (RG7596) in combination with bendamustine plus rituximab (Rituxan®; Genentech/Roche) against bendamustine plus...

Long-term Data of Brentuximab Vedotin Redifines Treatment of Frontline Mature T-Cell...

Data highlighted at the 59th annual meeting of the American Society of Hematology (ASH) held in Atlanta, Georgia, December 9-12, 2017 shows final five-year...

Ladiratuzumab Vedotin (SGN-LIV1A) in Triple Negative Breast Cancers Shows a 29%...

Updated data from an ongoing Phase I clinical trial evaluating ladiratuzumab vedotin (SGN-LIV1A) in patients with metastatic triple negative breast cancer (mTNBC), was presented...

Antibody-Drug Conjugates at the 59th American Society of Hematology Annual...

This year, in Atlanta, the South's largest and most vibrant city, the 59th annual meeting and exposition of the American Society of Hematology, to...